BIBLIOGRAFIA
- Smith DB, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology, Vol. 59, No. 1, 2014.
- Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39:5-19
- Koutsoudakis G, Forns X, Perez-Del-Pulgar S. Biología molecular aplicada del virus de la hepatitis C. Gastroenterol Hepatol 2013; 36:280-93.
- WHO. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Abril 2014. Disponible en: http://www.who.int/hiv/topics/hepatitis/en/
- Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014 ;61:S45-57.
- Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383-98
- Loomba R, Rivera MM, McBurney R, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011;33:559-65.
- Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35
- Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296-305.
- Fernández-Rodríguez C, Gutiérrez-García ML. Impacto del tratamiento antiviral en la historia natural del virus de la hepatitis C. Gastroenterol Hepatol. 2014;37(10):583-592.
- Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999;42:2204-12.
- EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2016; http://dx.doi.org/10.1016/j.jhep.2016.09.001
- Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93.
- Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, et al. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH.Med Clin (Barc). 2016 Jun; 146(11):511.e1-511.e22.
- Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
- Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 2015; 149:1345–1360.
- Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
- Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
- Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
- Agencia Española del Medicamento.Centro de informacion del medicamento. Fichas técnicas. https://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=buscar
- Guías AEEH/SEIMC de manejo de la Hepatitis C. Actualización de Enero 2017. http://aeeh.es/wp-content/uploads/2016/06/Gu%C3%ADas_AEEH_SEIMC_VersionFinal.pdf
- Plan Estratégico para el abordaje de la hepatitis C en el sistema nacional de Salud. Publicado por Ministerio de Sanidad, Servicios Sociales e Igualdad. 21 de Mayo de 2015. https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/plan_estrategico_hepatitis_C.pdf
- Resumen de recomendaciones para el tratamiento de hepatitis C. (Consultado el 6 Marzo 2017). Disponible en: http://aeeh.es/wp-content/uploads/2017/01/Tabla-recomendaciones_AEEH_SEIMC_DIC16.pdf